Differential microRNA expression in the SH-SY5Y human cell model as potential biomarkers for Huntington’s disease DOI Creative Commons
Ayaz M. Belkozhayev, Raigul Niyazova, Mohammad Amjad Kamal

и другие.

Frontiers in Cellular Neuroscience, Год журнала: 2024, Номер 18

Опубликована: Июль 10, 2024

Huntington’s disease (HD) is caused by an expansion of CAG trinucleotide repeat in the HTT gene; exact pathogenesis HD currently remains unclear. One promising directions study HDs to determine molecular mechanism underlying development and role microRNAs (miRNAs). This aimed identify profile miRNAs human cell line model as diagnostic biomarkers for HD. To HD, SH-SY5Y based on expression two different forms: pEGFP-Q23 pEGFP-Q74 HTT. The Htt protein was confirmed using aggregation assays combined with immunofluorescence Western blotting methods. miRNA levels were measured neuronal samples stably expressing Q23 Q74 extraction-free HTG EdgeSeq protocol. A total 2083 detected, 354 (top 18 miRNAs) significantly differentially expressed (DE) ( p < 0.05) lines. majority downregulated model. Moreover, we revealed that six DE target seven genes ATN1, GEMIN4, EFNA5 , CSMD2, CREBBP, ATXN1, B3GNT ) play important roles neurodegenerative disorders showed significant differences mutant (Q74) when compared wild-type (Q23) RT-qPCR 0.05 0.01). We demonstrated most miRNA-mRNA profiles, interaction binding sites, their related pathways experimental bioinformatics will allow novel strategies provide alternative therapeutic routes treating

Язык: Английский

Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives DOI
Zhijia Li, Bo Yin,

Shuangqian Zhang

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2023, Номер 261, С. 115817 - 115817

Опубликована: Сен. 14, 2023

Язык: Английский

Процитировано

30

Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease DOI Creative Commons
Tao Zhang, Byeong Mo Kim, Tae Ho Lee

и другие.

Translational Neurodegeneration, Год журнала: 2024, Номер 13(1)

Опубликована: Янв. 9, 2024

Alzheimer's disease (AD) is the most prevalent form of dementia in elderly and represents a major clinical challenge ageing society. Neuropathological hallmarks AD include neurofibrillary tangles composed hyperphosphorylated tau, senile plaques derived from deposition amyloid-β (Aβ) peptides, brain atrophy induced by neuronal loss, synaptic dysfunctions. Death-associated protein kinase 1 (DAPK1) ubiquitously expressed central nervous system. Dysregulation DAPK1 has been shown to contribute various neurological diseases including AD, ischemic stroke Parkinson's (PD). We have established an upstream effect on Aβ tau pathologies apoptosis through kinase-mediated phosphorylation, supporting causal role pathophysiology AD. In this review, we summarize current knowledge about how involved pathological changes hyperphosphorylation, deposition, cell death degeneration. The underlying molecular mechanisms dysregulation are discussed. also review recent progress regarding development novel modulators their potential applications intervention. These findings substantiate as therapeutic target for multifunctional disease-modifying treatments other disorders.

Язык: Английский

Процитировано

12

Melatonin: A potential nighttime guardian against Alzheimer’s DOI Creative Commons
Z Zhang, Pei Xue, Barbara B. Bendlin

и другие.

Molecular Psychiatry, Год журнала: 2024, Номер unknown

Опубликована: Авг. 11, 2024

In the context of escalating global health challenge posed by Alzheimer's disease (AD), this comprehensive review considers potential melatonin in both preventive and therapeutic capacities. As a naturally occurring hormone robust antioxidant, accumulating evidence suggests is compelling candidate to consider AD-related pathologies. The several mechanisms, including effects on amyloid-beta pathologic tau burden, antioxidant defense, immune modulation, regulation circadian rhythms. Despite its promise, gaps need be addressed prior clinical translation. These include conducting additional randomized trials patients with or at risk for AD dementia, determining optimal dosage timing, further side effects, particularly long-term use. This consolidates existing knowledge, identifies gaps, directions future research better understand neuroprotection mitigation within landscape AD.

Язык: Английский

Процитировано

11

The role of Cdk5 in neurological disorders DOI Creative Commons

Chuncao Ao,

Chenchen Li,

Jinlun Chen

и другие.

Frontiers in Cellular Neuroscience, Год журнала: 2022, Номер 16

Опубликована: Июль 28, 2022

Neurological disorders are a group of with motor, sensory or cognitive damage, caused by dysfunction the central peripheral nervous system. Cyclin-dependent kinases 5 (Cdk5) is vital significance for development system, including migration and differentiation neurons, formation synapses, axon regeneration. However, when system subject to pathological stimulation, aberrant activation Cdk5 will induce abnormal phosphorylation variety substrates, resulting in cascade signaling pathway, thus lead changes. intimately related mechanism neurological disorders, such as A-β protein Alzheimer’s disease, mitochondrial fragmentation cerebral ischemia, apoptosis dopaminergic neurons Parkinson’s disease. It worth noting that inhibitors have been reported neuroprotective effects inhibiting processes. Therefore, this review, we briefly introduce physiological mechanisms focusing on recent advances prospect targeted treatment disorders.

Язык: Английский

Процитировано

35

Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease DOI Open Access
Long Wang,

Xindong Shui,

Yuelin Diao

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(22), С. 16259 - 16259

Опубликована: Ноя. 13, 2023

Alzheimer’s disease (AD) is a complex multifactorial disorder that poses substantial burden on patients, caregivers, and society. Considering the increased aging population life expectancy, incidence of AD will continue to rise in following decades. However, molecular pathogenesis remains controversial, superior blood-based biomarker candidates for early diagnosis are still lacking, effective therapeutics halt or slow progression urgently needed. As powerful genetic regulators, microRNAs (miRNAs) receiving increasing attention due their implications initiation, development, theranostics various diseases, including AD. In this review, we summarize miRNAs directly target microtubule-associated protein tau (MAPT), amyloid precursor (APP), β-site APP-cleaving enzyme 1 (BACE1) transcripts regulate alternative splicing APP. We also discuss related kinases, such as glycogen synthase kinase (GSK)-3β, cyclin-dependent 5 (CDK5), death-associated (DAPK1), well apolipoprotein E, targeted by control phosphorylation amyloidogenic APP processing leading Aβ pathologies. Moreover, there evidence miRNA-mediated modulation inflammation. Furthermore, circulating serum plasma patients noninvasive biomarkers with diagnostic potential reviewed. addition, miRNA-based optimized nanocarriers exosomes options treatment discussed.

Язык: Английский

Процитировано

19

The underlying roles and neurobiological mechanisms of music-based intervention in Alzheimer's disease: A comprehensive review DOI
Liyang Sun, Qin Wang, Jing Ai

и другие.

Ageing Research Reviews, Год журнала: 2024, Номер 96, С. 102265 - 102265

Опубликована: Март 12, 2024

Язык: Английский

Процитировано

6

miR-143-3p Inhibits Aberrant Tau Phosphorylation and Amyloidogenic Processing of APP by Directly Targeting DAPK1 in Alzheimer’s Disease DOI Open Access
Long Wang,

Xindong Shui,

Yingxue Mei

и другие.

International Journal of Molecular Sciences, Год журнала: 2022, Номер 23(14), С. 7992 - 7992

Опубликована: Июль 20, 2022

The neuropathology of Alzheimer’s disease (AD) is characterized by intracellular aggregation hyperphosphorylated tau and extracellular accumulation beta-amyloid (Aβ). Death-associated protein kinase 1 (DAPK1), as a novel therapeutic target, shows promise for the treatment human AD, but regulatory mechanisms DAPK1 expression in AD remain unclear. In this study, we identified miR-143-3p promising candidate targeting DAPK1. directly bound to 3′ untranslated region mRNA inhibited its translation. decreased phosphorylation promoted neurite outgrowth microtubule assembly. Moreover, attenuated amyloid precursor (APP) reduced generation Aβ40 Aβ42. Furthermore, restoring with antagonized effects attenuating hyperphosphorylation Aβ production. addition, levels were downregulated correlated inversely hippocampus patients. Our results suggest that might play critical roles regulating both aberrant amyloidogenic processing APP thus offer potential strategy AD.

Язык: Английский

Процитировано

26

Neuroprotection and Mechanism of Gas-miR36-5p from Gastrodia elata in an Alzheimer’s Disease Model by Regulating Glycogen Synthase Kinase-3β DOI Open Access
Zhongteng Lu,

Jianyuan Fu,

Guang Wu

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(24), С. 17295 - 17295

Опубликована: Дек. 9, 2023

Alzheimer’s disease (AD) is currently the most common neurodegenerative disease. Glycogen synthase kinase 3β (GSK-3β) a pivotal factor in AD pathogenesis. Recent research has demonstrated that plant miRNAs exert cross-kingdom regulation on target genes animals. Gastrodia elata (G. elata) valuable traditional Chinese medicine significant pharmacological activity against diseases of central nervous system (CNS). Our previous studies have indicated G. elata-specific miRNA plays regulatory role for NF-κB signaling pathway mice. In this study, further bioinformatics analysis suggested Gas-miR36-5p targets GSK-3β. Through western blot, RT-qPCR, and assessments T-AOC, SOD, MDA levels, its neuroprotective effects an cell model. Furthermore, was detected murine brain tissues. The results Morris water maze test blot provided positive evidence reversing learning deficits hyperphosphorylation Tau mice, elucidating model following RNA administration. emphasizes as novel with properties by targeting Consequently, our findings provide insights into mechanisms underlying miRNA, presenting perspective treatment

Язык: Английский

Процитировано

14

Curcumin hybrid molecules for the treatment of Alzheimer's disease: Structure and pharmacological activities DOI

Wei-Biao Zang,

Huiling Wei,

Weiwei Zhang

и другие.

European Journal of Medicinal Chemistry, Год журнала: 2023, Номер 265, С. 116070 - 116070

Опубликована: Дек. 18, 2023

Язык: Английский

Процитировано

13

Bridging neurotrophic factors and bioactive peptides to Alzheimer's disease DOI
Minhui Wei, Tong Wu, Ning Chen

и другие.

Ageing Research Reviews, Год журнала: 2023, Номер 94, С. 102177 - 102177

Опубликована: Дек. 22, 2023

Язык: Английский

Процитировано

11